Postherpetic Neuralgia
Conditions
Brief summary
Investigate the Efficacy and Safety of HSK16149 capsules in Chinese Postherpetic Neuralgia Following 12 Weeks Treatment in Comparison to Placebo
Interventions
HSK16149 20mg, orally twice a day, treatment period; 12-weeks fixed dose
HSK16149 40mg, orally twice a day, treatment period; 12-weeks fixed dose
DRUGPlacebo BID
Placebo, orally twice a day, treatment period; 12-weeks fixed dose
Sponsors
Haisco Pharmaceutical Group Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Signed informed consent; 2. Males or females aged 18-75 years of age inclusive; 3. Outpatient, Patients can not stay in the hospital overnight; 4. Patients must have pain present for more than 1 months after the healing of the herpes zoster skin rash; 5. At Screening, pain scale (VAS) of ≥40 mm;
Exclusion criteria
1. Peripheral neuropathy or pain unrelated to PHN that may confuse the assessment of PHN; 2. Skin conditions in the area affected by neurupathy that could alter sensation; 3. Chronic systemic diseases that may affect subjects' participation in the study; 4. Severe hematologic, hepatic or renal dysfunction, the subject will be excluded if:1)Neutrophils \< 1.5 × 109/L, or platelet \< 90 × 109/L, or hemoglobin \< 100 g/L, or 2)AST/ALT \> 2.5 × upper limit of normal (ULN), or TBIL \> 1.5 × ULN, or 3)Estimation of glomerular filtration rate (eGFR) \< 60 mL/min / 1.73 m2, or 4)Creatine kinase \> 2.0 × ULN. 5. Uncontrolled diabetes(HbA1c≥11.0% at screening) ; 6. History of substance abuse or alcohol abuse; 7. Any active infections at screening; 8. HBsAg or HCV Ab positive, or HIV Ab positive, or serum TP Ab positive; 9. Inability or unwillingness to discontinue any other prohibited concomitant medications (see Section 6.3); 10. Patients who have undergone neurolytic or neurosurgical therapy 1 week before screening for postherpetic neuralgia; 11. Failure to response to previous treatment with pregabalin at doses ≥ 300 mg/d or gabapentin at doses ≥ 1200 mg/d for treatment of PHN; 12. History of allergic or medically significant adverse reaction to investigational products or their excipients, acetaminophen or related compounds; 13. History of suicidal behavior or attempted suicide; 14. Pregnant or preparing for pregnancy or breastfeeding during the study period, or subjects were not willing to use reliable contraceptives methods from the date of ICF signature until 28 days after the last trial drug administration, or planning to use progesterone contraceptives during this period; 15. Mechanical operators who are engaged in high-altitude operations, motor vehicle driving and other dangerous machinery operators; 16. Participated in another clinical study within 30 days prior to screening; 17. Other conditions unlikely to participate in this trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Compare the change from baseline in ADPS between HSK16149 and placebo at week 12 | Baseline and week 12 | The mean change in average daily pain score (ADPS) was measured using a 11-point numeric rating scale (NRS; 0 \[no pain\] to 10 \[worst possible pain\]. The rating averaged over a 7-day period and was based on entries in patients' daily pain diaries |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Compare the change from baseline in ADPS between HSK16149 and placebo at week 1 to 12 | From week 1 to week 12 | The mean change in average daily pain score (ADPS) was measured using a 11-point numeric rating scale (NRS; 0 \[no pain\] to 10 \[worst possible pain\]. The rating averaged over a 7-day period and was based on entries in patients' daily pain diaries |
| Compare the change from baseline in Visual Analogue Scale（VAS） between HSK16149 and placebo at week 12 | Baseline and week 12 | VAS, in which the participant rates pain on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain |
| Compare the change from baseline in Short Form McGill Pain Questionnaire (SF-MPQ) between HSK16149 and placebo at week 12 | Baseline and week 12 | Participants rate their pain in three parts of the questionnaire, which are combined into a single pain intensity score: Part 1 - fifteen descriptors of pain intensity, on a scale of 0 (none) to 3 (severe) Part 2 - a visual analog scale (VAS), in which the participant rates pain on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain Part 3 - a Present Pain Intensity index in which the participant rates present pain intensity on a scale of 0 (no pain) to 5 (most intense pain) |
| Compare the change from baseline in Average Daily Sleep interference score（ADSIS） between HSK16149 and placebo at week 12 | Baseline and week 12 | he sleep interference scores on a scale of 0-10, where 0 = pain did not interfere with sleep to 10 = pain completely interfered with sleep. The weekly ADSIS is based on participants daily sleep interference scores |
| Compare the response rate between HSK16149 and placebo at week 12 (Proportion of subjects whose ADPS decreased by ≥30% and ≥50% from baseline ) | Baseline and week 12 | Ratio of Participants Responding to Treatment, as Measured by Average Daily Pain Score (ADPS) Reduction from Baseline. The ADPS is used to determine categorical response rates. |
| Compare the change from baseline in EQ-5D-5L between HSK16149 and placebo at week 12 | Baseline and week 12 | The change from baseline in total EuroQol-5-Domain-5-Level health questionnaire |
| AE（adverse event） to evaluate the safety of HSK16149 during the trial | From week 1 to week 12 | Number and severity of AEs |
| Peak Plasma Concentration (Cmax) of HSK16149 capsules in Chinese patients with Postherpetic Neuralgia | Week 4,week 8,week 10,week 12 | — |
| Area under the plasma concentration versus time curve (AUC) of HSK16149 capsules in Chinese patients with Postherpetic Neuralgia | Week 4,week 8,week 10,week 12 | — |
| Compare the total consumption of Acetaminophen and Paracetamol and Dihydrocodeine Tartrate between HSK16149 and placebo during the trial | From week 1 to week 12 | — |
Countries
China
Outcome results
None listed